Accéder au contenu
Merck

Sirt3 Exerts Its Tumor-Suppressive Role by Increasing p53 and Attenuating Response to Estrogen in MCF-7 Cells.

Antioxidants (Basel, Switzerland) (2020-04-05)
Marija Pinterić, Iva I Podgorski, Marijana Popović Hadžija, Vedrana Filić, Mladen Paradžik, Bastien Lucien Jean Proust, Ana Dekanić, Ivan Ciganek, Denis Pleše, Dora Marčinko, Tihomir Balog, Sandra Sobočanec
RÉSUMÉ

Estrogen (E2) is a major risk factor for the initiation and progression of malignancy in estrogen receptor (ER) positive breast cancers, whereas sirtuin 3 (Sirt3), a major mitochondrial NAD+-dependent deacetylase, has the inhibitory effect on the tumorigenic properties of ER positive MCF-7 breast cancer cells. Since it is unclear if this effect is mediated through the estrogen receptor alpha (ERα) signaling pathway, in this study, we aimed to determine if the tumor-suppressive function of Sirt3 in MCF-7 cells interferes with their response to E2. Although we found that Sirt3 improves the antioxidative response and mitochondrial fitness of the MCF-7 cells, it also increases DNA damage along with p53, AIF, and ERα expression. Moreover, Sirt3 desensitizes cells to the proliferative effect of E2, affects p53 by disruption of the ERα-p53 interaction, and decreases proliferation, colony formation, and migration of the cells. Our observations indicate that these tumor-suppressive effects of Sirt3 could be reversed by E2 treatment only to a limited extent which is not sufficient to recover the tumorigenic properties of the MCF-7 cells. This study provides new and interesting insights with respect to the functional role of Sirt3 in the E2-dependent breast cancers.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
MISSION® esiRNA, targeting human SIRT3